Archives
- 2018-07
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
- 2025-02
- 2025-03
-
br GPR a G protein coupled receptor GPCR was discovered
2021-12-21
GPR35, a G protein-coupled receptor (GPCR), was discovered and classified as an orphan GPCR in 1998 and deorphanized in 2006 by the discovery of kynurenic the full details as the endogenous agonist. Since its discovery, limited references on the GPR35 receptor have appeared, due in part to a scar
-
Introduction Nicotinic acid niacin NA has been used
2021-12-21
Introduction Nicotinic galanin (niacin, NA) has been used in the treatment of dislipidemia and cardiovascular disease for almost 60years (Offermanns, 2006). Large clinical studies showed that niacin alone or in combination with LDL-lowering drugs improved cardiovascular outcomes (Canner et al., 198
-
br Materials and methods br Acknowledgements The following
2021-12-21
Materials and methods Acknowledgements The following reagents were obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: SIVagm155-4 from Dr. Vanessa Hirsch and Dr. Philip Johnson; Anti-SIVmac251 Polyclonal; SIVagm tan-1 infectious molecular ml to moles from Drs. Marcel
-
Reports of hyperlocomotion after administration of ALX
2021-12-21
Reports of hyperlocomotion after administration of ALX-5407 [27] coupled with the lack of hyperlocomotion after administration of SSR504734, a non-sarcosine, long-residence time, competitive inhibitor [19], suggested that the GlyT1 inhibitor chemotype may impact OP. Furthermore, a compound with a co
-
Up to now many UDG assays have been reported
2021-12-21
Up to now, many UDG assays have been reported based on the design of dU-containing substrate DNA, which can be roughly divided into two categories according to the sensing mechanisms. One type of UDG assays are simply based on the physical or chemical property changes of the substrate accompanied wi
-
br Methods br Acknowledgements The authors thank
2021-12-21
Methods Acknowledgements The authors thank the ZLS group members, particularly Li Li and Elijah Roberts, for many helpful discussions. They also wish to thank Nathan Baker for APBS assistance, Jan Jensen for help with PROPKA 2.0, Susan Martinis for experimental interpretations, and John Stone
-
WIKI4 australia Extending time action is another
2021-12-21
Extending time action is another strategy to increase in vivo efficacy. Twice daily administration of the unacylated analogs herein caused greater body weight loss in DIO mice than the equivalent dose administered as a single daily injection, suggesting that protracted time action should yield more
-
br Author contributions br Transparency
2021-12-21
Author contributions Transparency document Acknowledgments The financial contributions of the Marie-Curie Action: BIOCONTROL, contract number MCRTN – 33439, the Agence Nationale de la Recherche (projects membraneDNP 12-BSV5-0012, MemPepSyn 14-CE34-0001-01, InMembrane 15-CE11-0017-01 and the
-
atp gamma s The schematic diagram of the
2021-12-21
The schematic diagram of the antagonistic interactions of Zn2+ and neurosteroids (NSs) at GABA-A receptors is summarized in Fig. 7. Neurosteroids exhibit powerful seizure protective effects against experimental seizures probably through the potentiation of synaptic and extrasynaptic GABA-A receptor-
-
Compound and several additional FPR antagonists identified h
2021-12-21
Compound 10 and several additional FPR1 antagonists identified here specifically blocked fMLF-induced responses mediated via FPR1 in FPR1-HL60 abk and human neutrophils, but not responses mediated via FPR2 or FPR3 (in human neutrophils and transfected HL60 cells) or Fpr1 (murine neutrophils and tran
-
br Materials and methods br Results br
2021-12-21
Materials and methods Results Discussion Induction of neuronal cell death is the main neurotoxic mechanism of arsenite (Vahidnia et al., 2007). Previous studies have demonstrated that arsenite may trigger neuronal cell death via apoptosis, autophagy as well as necrosis (Yen et al., 2012; La
-
On correlating acute rejection to different risk markers
2021-12-21
On correlating acute rejection to different risk markers by multiple linear regression analysis, we found that serum FasL and serum creatinine were variables that were independently associated with AR. Carstens et al., reported that significant differences were present between acute rejection and ze
-
We thus asked whether enhanced AEA
2021-12-20
We thus asked whether enhanced AEA levels in the ritodrine reduce the level of age-related inflammatory changes and slow down brain ageing. To answer this question we compared the morphology of microglia and level of pro-inflammatory cytokines in the hippocampus of young and old wild-type and FAAH−/
-
br Experimental br Acknowledgments br Human immunodeficiency
2021-12-20
Experimental Acknowledgments Human immunodeficiency virus-1 (HIV-1) is the causative agent of acquired immunodeficiency syndrome (AIDS), and without treatment results in a debilitating disease that cripples the immune system of the patient, increasing susceptibility to opportunistic diseases
-
KDM D also known as JARID D or
2021-12-20
KDM5D (also known as JARID1D or SMCY) is encoded on the Y chromosome and until now it has been implicated in prostate cancer invasion and metastasis [42], spermatogenesis [43], and sex-specific tissue transplantation rejection [44]. KDM5D acts as a direct epigenetic modulator, and as one of the four
14786 records 510/986 page Previous Next First page 上5页 506507508509510 下5页 Last page